Quick Answer
MediWound Ltd. reported R&D Expense of $14.32 million for fiscal year 2025.
MediWound Ltd. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $14.32M | +61.3% |
| 2024 | $8.88M | +18.9% |
| 2023 | $7.47M | -26.7% |
| 2022 | $10.18M | -0.7% |
| 2021 | $10.26M | +33.2% |
| 2020 | $7.70M | +54.9% |
| 2019 | $4.97M | +22.0% |
| 2018 | $4.07M | -25.4% |
| 2017 | $5.46M | -22.7% |
| 2016 | $7.07M | +17.4% |
| 2015 | $6.02M | — |
- MediWound Ltd. showed an increase of +61.3% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, MediWound Ltd.’s r&d expense has grown by 137.8% (from $6.02 million to $14.32 million).
- The most recent figure is from MediWound Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: